Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Tumor Specific TCR-T Cells in Advanced Solid Tumors
NCT03891706Phase 1Recruiting
- Sponsor
- Guangzhou FineImmune Biotechnology
- Start
- Jan 2019
- Primary completion
- Oct 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FIT-001 in solid tumor (advanced stage), sponsored by Guangzhou FineImmune Biotechnology. Primary endpoint: Number of participants with treatment-related adverse events at 45 days. Started Jan 2019; status: recruiting.
02
Drugs
FIT-001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03891706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891706.